Alpha blockers: are all created equal? (Q34080452)

30 July 2017

1 reference

title

Alpha blockers: are all created equal? (English)

1 reference

30 July 2017

Debruyne FM

1

1 reference

PubMed ID

11074198

30 July 2017

language of work or name

English

0 references

publication date

1 November 2000

1 reference

30 July 2017

1 reference

30 July 2017

56

1 reference

30 July 2017

5 Suppl 1

1 reference

30 July 2017

20-22

1 reference

Some Clinical Implications of Adrenergic Receptors in the Urinary Tract

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900744-5

7 January 2021

Localization and expression of the alpha1A-1, alpha1B and alpha1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900744-5

7 January 2021

Tamsulosin : A Review of its Pharmacological Properties and Therapeutic Potential in the Management of Symptomatic Benign Prostatic Hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900744-5

7 January 2021

The concept of uroselectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900744-5

7 January 2021

[Treatment of benign prostatic hyperplasia with alpha 1-adrenoreceptor antagonists]

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900744-5

7 January 2021

Pharmacotherapy for benign prostatic hyperplasia--the potential for alpha 1-adrenoceptor subtype-specific blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900744-5

7 January 2021

A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900744-5

7 January 2021

Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900744-5

7 January 2021

Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900744-5

7 January 2021

Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900744-5

7 January 2021

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900744-5

7 January 2021

10.1016/S0090-4295(00)00744-5

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

11074198